CP3’s own Dr. Tim Anderson was interviewed for a New York Times story examining recent trends in the use of GLP-1 weight-loss medications among older adults and the factors driving changes in patient...
Congratulations to Yujin Seo, a doctoral student from CMU who is working with CP3’s Dr. Katie Suda on her Drug Shortages project. Yujin presented at the IQVIA Institute Research Forum in September...
CP3's Dr. Luke Berenbrok spoke with Newsweek about ways that Medicare users can ensure they are using all of their benefits, especially those for OTC items. He suggests talking with community...
A new Ars Technica piece highlights work by CP3’s Dr. Tim Anderson, showing that GLP-1 drugs improve heart health, but benefits fade when treatment stops—raising important questions about long-term...
CP3 Associate Director Dr. Katie Suda was interviewed for Dr. Bicuspid on the risks of prescribing opioids to pediatric patients. Results of a recent study published in JADA "emphasize the need for...
We are proud to announce that CP3 faculty affiliate Dr. Bryant Shuey, MD, MPH has been selected as a 2025–26 State Health Policy Fellow by the National Academy of Medicine.
The University of Florida College of Pharmacy has received a $3.6 million grant from the National Institute on Drug Abuse (NIDA) to fund the PROTECT project, which will develop an artificial...
CP3’s Dr. Tom Radomski received a new VA Merit grant to lead EVOLV-Rx VA, a study aimed at reducing low-value prescribing in VA Community Living Centers. The project will use an EVOLV-Rx dashboard to...
Congratulations to CP3 Director Dr. Walid Gellad and the mPROVEN study team on a new award to create a playbook for ethical use of machine learning-based opioid risk prediction models, building on...
We are thrilled to announce a new R01 grant award for the study “Developing a ML algorithm to predict relapse in OUD treatment and building an evidence-based clinical decision support (CDS) e-tool...
